Treatment with MiR-124 led to BACE1 downregulation at protein and RNA levels in addition to reducing Tau but not APP via the regulation of the autophagy pathway for reversing the over-expressing autophagy markers p62, Atg5, and LC3II proteins in the AD patients, and this is thought to lessen the symptoms of AD pathogenesis. Here, ATG5 is linked to Alzheimer disease.